Investigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes
This study is investigating a new medicine called NNC0487-0111, for adults living with Type 2 diabetes. The main goal is to understand how this potential new treatment affects how your body uses insulin – the hormone that helps manage your blood sugar levels. Researchers also want to see how it impacts the work of your pancreas, the organ that produces insulin. Some participants will receive NNC0487-0111, while others will get a placebo, which looks the same but contains no active medicine. The choice of treatment is made by chance. This is an early stage study, designed to assess the medicine's effects in a small group of people.
Överblick
Vad handlar denna studie om?
This research study is looking into a new medicine, called NNC0487-0111, for people who have Type 2 diabetes. Diabetes is a condition where your body struggles to use insulin properly, or doesn't make enough of it, leading to high blood sugar levels. Insulin is a really important hormone that helps sugar get from your blood into your cells to be used for energy.
The main purpose of this study is to find out exactly how NNC0487-0111 affects how your body uses insulin and how well your pancreas, the organ that makes insulin, is working. By understanding this, doctors hope to learn more about how this new medicine could help manage blood sugar in people with Type 2 diabetes.
This is an early stage study, meaning it's one of the first times this medicine is being tested in people. Early studies help researchers learn important information about new medicines, such as how they work and if they are safe, before they can be tested in larger groups.
Viktiga punkter
- This study is testing a new medicine (NNC0487-0111) for Type 2 diabetes.
- It aims to understand how the medicine affects insulin and pancreas function.
- You might receive the new medicine or a 'dummy' treatment (placebo).
- Your health will be closely monitored by a specialist team.
- You can stop participating in the study at any time if you wish.
- This is an early-stage study to gather important information.
Vem kan vara berättigad?
To join this study, you need to be an adult between 18 and 75 years old and have been diagnosed with Type 2 diabetes for at least 6 months. You should be taking metformin at a stable dose, or metformin alongside another diabetes medicine called an SGLT2i, and these doses should have been consistent for at least three months.
Your blood sugar control, measured by a test called HbA1c, needs to be within a specific range. For example, if you're only on metformin, your HbA1c should be between 6.5% and 9.5%. If you're on metformin with an SGLT2i, it should be between 6.0% and 9.0%.
You cannot join if you are pregnant, breastfeeding, or planning to become pregnant without using effective contraception. You also can't participate if you have Type 1 diabetes, have had significant weight changes or been on a strict diet recently, or have certain eye conditions related to diabetes that have needed recent treatment or are expected to need it soon. Taking certain other diabetes medicines or weight management drugs also means you can't take part.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Är du mellan 18 och 75 år gammal?
- Har du haft typ 2-diabetes i minst 6 månader?
- Are you currently taking metformin, or metformin with an SGLT2i, at a stable dose for at least 3 months?
- Are you not pregnant, breastfeeding, or planning to get pregnant without effective contraception?
- Do you not have Type 1 diabetes?
- Have you not had recent significant weight changes (5% or more in 3 months) or been on a strict diet?
Vad innebär deltagande?
This study involves receiving either the new medicine, NNC0487-0111, or a placebo, which looks identical but has no active ingredients. You won't know which one you're getting, as this is decided randomly, like flipping a coin. This helps ensure the results are fair and unbiased. The study will involve regular visits to the clinic where you'll have various tests, such as blood samples, to see how your body is responding to the treatment. The overall duration of the study, including the number of visits and follow-up, will be fully explained by the study team if you are suitable to take part.
Potentiella risker och fördelar
Platser (1)
- Profil Institut für Stoffwechselforschung GmbHVerifierat postnummerNeuss, Germany· Rekrytering
Vanliga frågor
Vad är typ 2-diabetes?
Type 2 diabetes is a condition where your body struggles to use insulin properly or doesn't make enough of it, leading to high blood sugar levels.
Vad är en placebo?
A placebo is a 'dummy' treatment that looks just like the real medicine but contains no active ingredients. It's used in studies to compare against the new medicine.
Kommer jag att veta om jag får den nya medicinen eller placebon?
No, you won't know directly. This is decided by chance to ensure the study results are fair and accurate.
Hur länge kommer jag att vara med i studien?
The full length of the study, including visits and follow-up, will be clearly explained if you are a suitable participant.
Kan jag lämna studien om jag ändrar mig?
Yes, you can leave the study at any time, for any reason, without it affecting your medical care.
Hur du får reda på mer
Novo Nordisk
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Intresserad av att delta?
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.